Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000288914 | SCV000337036 | uncertain significance | not provided | 2015-12-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001833334 | SCV001225004 | uncertain significance | Pontocerebellar hypoplasia type 1A | 2021-09-09 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine with lysine at codon 156 of the VRK1 protein (p.Gln156Lys). The glutamine residue is highly conserved and there is a small physicochemical difference between glutamine and lysine. This variant is present in population databases (rs201936978, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with VRK1-related conditions. ClinVar contains an entry for this variant (Variation ID: 284417). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The lysine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001833334 | SCV002093686 | uncertain significance | Pontocerebellar hypoplasia type 1A | 2020-09-08 | no assertion criteria provided | clinical testing |